A Genetic and Biochemical Perspective: Acute Coronary Syndrome and Raftlin
Rattachement africain : tr, us, gb. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background: Inflammation plays a central role in the pathophysiology of acute coronary syndrome (ACS). Raftlin, a lipid raft-associated inflammatory protein involved in immune signaling, has emerged as a potential biomarker in cardiovascular disease. This study aimed to evaluate circulating raftlin levels and RFTN1 rs690037 polymorphism in patients with ACS. Methods: This prospective observational study included 100 participants comprising 50 patients diagnosed with ACS and 50 control subjects with angiographically normal coronary arteries. Serum raftlin concentrations were measured using enzyme-linked immunosorbent assay, and RFTN1 rs690037 polymorphisms were analyzed by real-time polymerase chain reaction. Correlation, receiver operating characteristic (ROC), multivariable logistic regression, and net reclassification improvement (NRI) analyses were performed. Results: Serum raftlin levels were significantly higher in the ACS group compared with controls (4.28 [3.48–5.78] vs. 3.38 [2.66–4.23] ng/dL, p = 0.003). Raftlin levels demonstrated significant positive correlations with LDL cholesterol and HbA1c levels in ACS patients (p < 0.05 for both). ROC analysis showed that raftlin had moderate discriminative ability for ACS detection (AUC: 0.672, 95% CI: 0.570–0.762, p = 0.002). Although raftlin was not independently associated with ACS after multivariable adjustment, incorporation of raftlin into the baseline clinical model improved overall risk classification (NRI: 0.213, p = 0.041). No significant association was observed between RFTN1 rs690037 polymorphism and ACS or circulating raftlin levels. Conclusions: Circulating raftlin levels are elevated in patients with ACS and appear to reflect the inflammatory and metabolic dysregulation accompanying acute coronary events. Although raftlin alone demonstrated limited diagnostic performance, its incremental contribution to multimarker risk assessment models suggests potential utility as a complementary inflammatory biomarker in ACS. Larger multicenter studies are warranted to clarify its prognostic and translational significance.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- A Genetic and Biochemical Perspective: Acute Coronary Syndrome and Raftlin
- Date Crossref
- 06/06/2026
- Éditeur
- MDPI AG
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Mersin Şehir Eğitim ve Araştırma Hastanesi pays non établi dans la noticeÉtablissement de santé
-
Mersin Üniversitesi pays non établi dans la noticeUniversité ou école supérieure
-
Genesis Medical Center pays non établi dans la noticeÉtablissement de santé
-
State Hospital Department of Cardiology pays non établi dans la noticeÉtablissement de santé
-
Sivas State Hospital pays non établi dans la noticeÉtablissement de santé
-
Mersin City Education and Research Hospital Department of Cardiology pays non établi dans la noticeÉtablissement de santé
-
Mersin University Faculty of Medicine Hospital Department of Cardiology pays non établi dans la noticeUniversité ou école supérieure
-
Private Genesis Hospital Department of Cardiology pays non établi dans la noticeÉtablissement de santé
Mersin Şehir Eğitim ve Araştırma Hastanesi, Mersin Üniversitesi et Genesis Medical Center, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.